News and Business

Biotech Business - Vol. 12 Nbr. 10, October 1999

FDA REQUESTS MODIFICATIONS TO BLA FOR BEXXAR.

... Currently, SB Oncology markets Hycamtin(R) (topotecan hydrochloride), Kytril(R) (granisetron hydrochloride), Compazine(R) (prochlorperazine) and has novel agents in development. For more information, call 650/...

See more references to Antineoplastic agents in this document

Business Wire - August 28, 1998

Zeneca Pharmaceuticals and Roche Laboratories Inc. Intend to Co-Promote Nolvadex -- Tamoxifen Citrate -- in the United States.

See more references to Antineoplastic agents in this document

Worldwide Biotech - Vol. 10 Nbr. 12, December 1998

FDA APPROVES ZENECA'S NOLVADEX AFTER LANDMARK TRIAL FINDINGS.

See more references to Antineoplastic agents in this document

Journal of Drugs in Dermatology - Vol. 5 Nbr. 1, January 2006

Imatinib in dermatofibrosarcoma protuberans (DFSP).

See more references to Antineoplastic agents in this document

Business Wire - July 30, 1998

Techniclone Announces Fiscal Year-End Results.

... The company is also developing two additional technologies for the treatment of solid tumors, Vasopermeation Enhancement Agents (VEAs) and Vascular Targeting Agents (VTAs). ...

See more references to Antineoplastic agents in this document

Business Wire - July 28, 1998

Techniclone Negotiates Sale of Corporate Headquarters; Company Enters Into Ten-Year Leaseback of Property.

See more references to Antineoplastic agents in this document

Business Wire - July 17, 1998

Techniclone Announces Redemption of Warrants.

... The Company is also developing two additional technologies for the treatment of solid tumors, Vasopermeation Enhancement Agents (VEAs) and Vascular Targeting Agents (VTAs). ...

See more references to Antineoplastic agents in this document

Business Wire - August 05, 1998

Techniclone Announces Grant From NYSE Multinational Pharmaceutical Company to Initiate Phase I/II TNT Solid Tumor Trial.

... The Company is also developing two additional technologies for the treatment of solid tumors, Vasopermeation Enhancement Agents (VEA) and Vascular Targeting Agents (VTA). VEAs ...

See more references to Antineoplastic agents in this document

Biotech Business - Vol. 11 Nbr. 10, October 1998

TECHNICLONE REPORTS SUCCESSFUL RESULTS FROM TNT PHASE I STUDY

... The company is also developing two additional technologies for the treatment of solid tumors, Vasopermeation Enhancement Agents (VEA) and Vascular Targeting Agents (VTA). VEAs ...

See more references to Antineoplastic agents in this document

Business Wire - June 16, 1998

Matrix Pharmaceutical Reports Preliminary Data From Phase III Solid Tumor Program; Status of Phase III Trials in Head and Neck Cancer Also Described.

See more references to Antineoplastic agents in this document